From NVIDIA:

Digital biology and generative AI are revolutionizing healthcare, with NVIDIA at the forefront. Over a billion dollars in NVIDIA GPU computing is already consumed annually in healthcare. In drug discovery, R&D teams are now able to represent drugs inside a computer, accelerating the candidate selection process and reducing the need for physical experiments.

NVIDIA’s BioNeMo platform utilizes generative AI to allow researchers to develop, customize, and deploy foundation models for drug discovery. Pharmaceutical, techbio, and software companies are using BioNeMo to integrate generative AI into their research, reducing the need for experiments and, in some cases, replacing them entirely.

BioNeMo features a variety of pretrained biomolecular AI models, and NVIDIA is releasing cloud APIs that include foundation models from different sources. MolMIM generative chemistry model generates small molecules with user- specified properties, providing more precise control over the AI generation process.

Recursion, a biopharmaceutical company, is the first hosting partner offering an AI model through BioNeMo cloud APIs, with its Phenom-Beta model. Phenom-Beta provides insights about cell function and cell responses to drug candidates or genetic engineering through cellular microscopy images analysis.

Phenom-Beta’s training and development were enhanced with NVIDIA DGX SuperPOD reference architecture and further boosted by the addition of more than 500 NVIDIA H100 Tensor Core GPUs, resulting in one of the most powerful supercomputers in the biopharma industry.

Various companies and AI software vendors in the biotech sector are adopting NVIDIA BioNeMo for biological, chemical, and genomics research to accelerate drug discovery, protein engineering, and molecular design.

Innophore, Insilico Medicine, Terray Therapeutics, OneAngstrom, and Deloitte have all integrated BioNeMo cloud APIs into their platforms for protein design, drug discovery, molecular design, and AI solutions for clients in the biopharma industry. This allows unprecedented data connectivity and cutting-edge generative AI for accelerated drug discovery.

Learn more about NVIDIA BioNeMo and subscribe to NVIDIA healthcare news for more updates.



Read more: Generative AI Opening Next Era of Drug Discovery